tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Novavax Gains FDA Approval for Nuvaxovid Vaccine

Story Highlights
  • Novavax’s Nuvaxovid COVID-19 vaccine received FDA approval for high-risk groups.
  • The approval makes Nuvaxovid the only non-mRNA COVID-19 vaccine in the U.S. for 2025-2026.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Novavax Gains FDA Approval for Nuvaxovid Vaccine

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Novavax ( (NVAX) ) has issued an announcement.

On August 27, 2025, Novavax announced that the FDA approved its Nuvaxovid 2025-2026 formula, a protein-based COVID-19 vaccine, for adults 65 and older and individuals 12-64 with underlying conditions. The approval includes extending the vaccine’s shelf life to six months and requires postmarketing studies to assess safety and post-vaccination syndrome. This approval positions Novavax as the only provider of a non-mRNA COVID-19 vaccine in the U.S. for the 2025-2026 season, potentially impacting its market presence and stakeholder interests.

The most recent analyst rating on (NVAX) stock is a Hold with a $8.00 price target. To see the full list of analyst forecasts on Novavax stock, see the NVAX Stock Forecast page.

Spark’s Take on NVAX Stock

According to Spark, TipRanks’ AI Analyst, NVAX is a Neutral.

Novavax’s overall stock score reflects financial instability and operational challenges, despite positive technical indicators and valuation. The earnings call and corporate events provide optimism for future growth, but immediate financial risks remain significant.

To see Spark’s full report on NVAX stock, click here.

More about Novavax

Novavax, Inc. is a biotechnology company specializing in vaccine development, utilizing its proprietary protein-based nanoparticle technology and Matrix-M adjuvant. The company focuses on addressing global health challenges through innovation in infectious diseases and aims to expand its technology platform through partnerships and collaborations.

Average Trading Volume: 6,570,665

Technical Sentiment Signal: Sell

Current Market Cap: $1.22B

For an in-depth examination of NVAX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1